U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. ICLR
4. LAES
5. JPM
6. DRI
7. SPY
8. FUL
9. IONS
10. IBM

Go back to U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

Pfizer (PFE) stock can outperform even in a 'trough COVID' scenario says Goldman Sachs

January 10, 2023 1:43 PM EST

Pfizer (NYSE: PFE) management presented at an investor conference yesterday its Chief Executive Albert Bourla said to have reiterated plans for shaping Pfizer post-Covid.

Following the Pfizer presentation, Credit Suisse analyst Trung Huynh told investors in a note that Pfizer focused on the non-Covid side of the business.

"For the non-COVID sales, Dr. Bourla reiterated its 2020-25 mid-term guide of +6% and also first-time longer-term 2025-30 guidance of 6-10%, which comes in ahead of consensus expectations," wrote Huynh, who maintained... More

Morgan Stanley sees a risk to Pfizer's (PFE) EPS guidance

January 6, 2023 10:08 AM EST

In a note to clients Friday, Morgan Stanley analyst Terence Flynn said the firm sees downside risk to Pfizer's (NYSE: PFE) EPS guidance.

The analyst explained that Pfizer will provide 1st time 2023 guidance in conjunction with fourth-quarter earnings on January 31 and the company previously noted that they plan to... More